https://www.selleckchem.com/pr....oducts/Roscovitine.h
s were efficiently transferred to neonates, but declined quickly to below the protective threshold, particularly among those whose mothers had low antibody titres. Our findings suggest that maternal vaccination could be explored to provide neonatal protection against EV-A71 through maternal antibodies. Catch-up vaccination between ages 6 months to 5 years could provide protection to the approximately 30-90% of children that have not had natural EV-A71 infection by that age. National Science Fund for Distinguished Young Scholars, Nat
Curtir
Comentario
Compartilhar
